Skip to main content
Annex II Entry 427 20/10/2010

3,4-Dihydrocoumarin, when used as a fragrance ingredient

3,4-Dihydrocoumarin, when used as a fragrance ingredient is listed in Annex II as a prohibited substance for cosmetic products placed on the EU market.

Prohibited substance— Annex II, EU Regulation 1223/2009
Entry: 427

Chemical identity and properties

PubChem 2D chemical structure for CAS 119-84-6
CAS 119-84-6PubChem CID 660

Dihydrocoumarin

3,4-dihydrocoumarin is a chromanone that is the 3,4-dihydro derivative of coumarin. It has a role as a plant metabolite. It is functionally related to a coumarin. ChEBI

IUPAC name
3,4-dihydrochromen-2-one
Molecular formula
C9H8O2
Molecular weight
148.16 g/mol
Exact mass
148.052429494 Da
XLogP3
1.6
Topological polar surface area
26.3 Ų
Hydrogen-bond donors
0
Hydrogen-bond acceptors
2
Covalent units
1
Defined stereocentres
0

Also known as

3,4-dihydrocoumarinhydrocoumarinBenzodihydropyronemelilotin2-chromanone1,2-benzodihydropyronemelilotic lactoneMelilotine
16 more reported names
Oxochroman2H-1-Benzopyran-2-one, 3,4-dihydro-Chroman, 2-oxo-DihydrobenzopyroneUsaf do-12Coumarin, 3,4-dihydro-Meliotine2-Hydroxydihydrocinnamic acid lactoneNCI-C55890o-hydroxydihydrocinnamic acid lactoneFEMA No. 2381Hydrocinnamic acid, o-hydroxy-, delta-lactoneNM5K1Y1BT2CHEBI:16151NSC-10121RefChem:91117
External database identifiers

Evidence from additional scientific databases

NIH PubChem PUG-View
Exact identifier match660

Attributed physical-property, hazard, environmental and use annotations.

  • Substance: 3,4-Dihydrocoumarin Source: NTP Technical Reports
  • NTP Technical Report: TR-423: Toxicology and Carcinogenesis Studies of 3,4-Dihydrocoumarin (CASRN 119-84-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies) (1993 ) Source: NTP Technical Reports
  • Peer Review Date: 06/23/92 Source: NTP Technical Reports
  • Conclusion for Male Rat: Some Evidence Source: NTP Technical Reports
  • Conclusion for Female Rat: No Evidence Source: NTP Technical Reports
  • Conclusion for Male Mice: No Evidence Source: NTP Technical Reports
  • Conclusion for Female Mice: Some Evidence Source: NTP Technical Reports
  • Summary: Under the conditions of these 2-year gavage studies, there was some evidence of carcinogenic activity of 3,4-dihydrocoumarin in male F344/N rats based on increased incidences of renal tubule adenomas and focal hyperplasia. The transitional cell carcinomas in two 600 mg/kg males may also have been chemical related. There was no evidence of carcinogenic activity of 3,4-dihydrocoumarin in female F344/N rats receiving 150, 300, or 600 mg/kg. There was no evidence of carcinogenic activity of 3,4-dihydrocoumarin in male B6C3F1 mice receiving 200, 400, or 800 mg/kg. There was some evidence of carcinogenic activity in female B6C3F1 mice based on increased incidences of hepatocellular adenoma and hepatocellular adenoma or carcinoma (combined).; 3,4-Dihydrocoumarin caused ulcers, hyperplasia, and inflammation of the forestomach, parathyroid gland hyperplasia, and increased severity of nephropathy in male rats. Source: NTP Technical Reports
  • First Aid: EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.; SKIN: IMMEDIATELY flood affected skin with water while removing and isolating all contaminated clothing. Gently wash all affected skin areas thoroughly with soap and water. If symptoms such as redness or irritation develop, IMMEDIATELY call a physician and be prepared to transport the victim to a hospital for treatment.; INHALATION: IMMEDIATELY leave the contaminated area; take deep breaths of fresh air. If symptoms (such as wheezing, coughing, shortness of breath, or burning in the mouth, throat, or chest) develop, call a physician and be prepared to transport the victim to a hospital. Provide proper respiratory protection to rescuers entering an unknown atmosphere. Whenever possible, Self-Contained Breathing Apparatus (SCBA) shou Source: CAMEO Chemicals
  • Signal: Warning Source: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H302 (> 99.9%): Harmful if swallowed [Warning Acute toxicity, oral]; H317 (97.4%): May cause an allergic skin reaction [Warning Sensitization, Skin] Source: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P261, P264, P270, P272, P280, P301+P317, P302+P352, P321, P330, P333+P317, P362+P364, and P501 (click each P-code to see the statement) Source: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: Aggregated GHS information provided per 1702 reports by companies from 11 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Source: European Chemicals Agency (ECHA)
  • Signal: Warning Source: Hazardous Chemical Information System (HCIS), Safe Work Australia
  • GHS Hazard Statements: H302: Harmful if swallowed [Warning Acute toxicity, oral]; H317: May cause an allergic skin reaction [Warning Sensitization, Skin] Source: Hazardous Chemical Information System (HCIS), Safe Work Australia
  • Precautionary Statement Codes: P261, P264, P270, P272, P280, P301+P317, P302+P352, P321, P330, P333+P317, P362+P364, and P501 (click each P-code to see the statement) Source: Hazardous Chemical Information System (HCIS), Safe Work Australia

Mapped by: Existing checksum-valid CAS to unique PubChem CID match. Retrieved: 2026-08-31. Open source record

Scientific classifications and hazard annotations provide context and do not replace the market-specific regulatory decision shown above.

Additional source coverage and match status
SourceResultChecked
NIH PubChem PUG-ViewExact match2026-08-31

A recorded no-match is useful evidence that the source was checked; it is not a claim that the substance does not exist elsewhere.

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

Record details

Chemical name

3,4-Dihydrocoumarin, when used as a fragrance ingredient

Chemical / IUPAC name

3,4-Dihydrocoumarin; Melilotin

Regulatory information

Key data

Annex
Entry number
427

Inventory links for 3,4-Dihydrocoumarin, when used as a fragrance ingredient

Inventory Restriction reference
Ref 84648

DIHYDROCOUMARIN

CAS: 119-84-6
EC: 204-354-9

Direct matches are limited for this record, so nearby entries from Annex II are shown as well.

What Annex II means for 3,4-Dihydrocoumarin, when used as a fragrance ingredient

3,4-Dihydrocoumarin, when used as a fragrance ingredient is listed as a prohibited substance under Annex II of EU Cosmetics Regulation 1223/2009 and must not be intentionally added. Article 17 separately addresses unintended small quantities that are technically unavoidable under good manufacturing practice and compatible with the Article 3 safety requirement.

Formulators must screen their ingredients and raw materials to ensure none contain this substance. Suppliers should provide documentation confirming absence when requested.

This record is linked to 1 CosIng inventory ingredient for name and identifier cross-reference. The page also surfaces 12 related annex records with overlapping identifiers, annex logic or naming patterns.

Compliance checklist

  • Verify this substance is absent from all raw materials and finished formulations.
  • Request absence confirmation or CoA from raw material suppliers.
  • Document the screening result in the Product Information File (PIF).

Frequently asked questions

Yes. 3,4-Dihydrocoumarin, when used as a fragrance ingredient is listed in Annex II of EU Cosmetics Regulation 1223/2009 and is prohibited as an intentionally added cosmetic ingredient. Article 17 provides a narrow exception for unintended small quantities that are technically unavoidable under good manufacturing practice, provided the product remains safe under Article 3.

CAS 119-84-6 is the unique numerical identifier assigned to 3,4-Dihydrocoumarin, when used as a fragrance ingredient by the Chemical Abstracts Service. In cosmetic compliance work, the CAS number is used to cross-reference the substance across regulatory databases, raw material specifications and safety assessment reports. Multiple EU annex entries may share the same CAS number if the same substance appears under different conditions or in different annexes.

Use the INCI Checker tool on this site to paste your full ingredient list (INCI) and scan it against all Annex II–VI entries. The tool highlights any ingredients that match restricted, prohibited or allergen-flagged records. This is useful for rapid compliance screening of finished product formulas or raw material declarations.

Source note for Annex II record 3,4-Dihydrocoumarin, when used as a fragrance ingredient

This page summarizes one Annex II record for 3,4-Dihydrocoumarin, when used as a fragrance ingredient from public European Commission cosmetic materials and adds linked inventory or identifier matches when available.

Use this record page to review Annex II conditions for 3,4-Dihydrocoumarin, when used as a fragrance ingredient, but confirm any final regulatory decision against the current official annex wording and source files.

Tools & next steps

Check your formula

Paste a full INCI list to detect 3,4-Dihydrocoumarin, when used as a fragrance ingredient and other flagged EU annex records in one pass.

INCI Checker

Compare entries

Compare 3,4-Dihydrocoumarin, when used as a fragrance ingredient side by side with another annex record to review differences in restrictions, concentrations and annex placement.

Compare

Browse the annex

See all records in Annex II and compare regulatory conditions across substances in this annex.

Open Annex II